

Ex vivo myolysis with dual wavelengths diode laser system: macroscopic and histopathological examination

Maurizio Nicola D'Alterio^{1,*}, Francesco Scicchitano¹, Daniela Fanni², Gavino Faa², Antonio Simone Laganà³, Marco Noventa⁴, Felice Sorrentino⁵, Luigi Nappi⁵, Stefano Angioni¹

¹Department of Surgical Sciences, Division of Obstetrics and Gynecology, University of Cagliari, 09124 Cagliari, Italy

²Department of Medical Sciences and Public Health, Unit of Anatomic Pathology, University of Cagliari, 09124 Cagliari, Italy

³Department of Obstetrics and Gynecology, "Filippo del Ponte" Hospital, University of Insubria, 21100 Varese, Italy

⁴Department of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35121 Padua, Italy

⁵Department of Medical and Surgical Sciences, Institute of Obstetrics and Gynaecology, University of Foggia, 71121 Foggia, Italy

*Correspondence: mauridalte84@gmail.com (Maurizio Nicola D'Alterio)

DOI:10.31083/j.ceog4804138

This is an open access article under the CC BY 4.0 license (<https://creativecommons.org/licenses/by/4.0/>).

Submitted: 7 March 2021 Revised: 28 March 2021 Accepted: 9 April 2021 Published: 15 August 2021

Background: Uterine fibroids are the most common benign gynaecological tumours in women. When symptomatic, heavy menstrual bleeding is the principal manifestation of uterine fibroids. Nowadays, several conservative procedures have been utilized to discourage hysterectomy or myomectomy and great interest has been focused on laser energy technology associated with mini-invasive approaches. Diode lasers demonstrated many advantages in laparoscopic and hysteroscopic surgery. **Methods:** To evaluate the Dual Wavelength Diode Laser System (DWLS) ablation techniques for treating fibroids, we devised an experimental system for characterizing the myolysis fibre ablation performance with a particular fibre designed to create a thermal ablation in the centre of the myoma. All the myomas were used for the experiment after a total hysterectomy and their excision from the fresh uteri. The experiment setup was composed of two beaker containers filled with isotonic saline water, temperature monitoring myoma surface and water bath, a diode laser fibre and a diode laser energy deposition system. **Results:** Good macroscopic results have been found for fibroids of about 60 cm³ ablated with a setting of 10 W of 980 nm + 10 W of 1470 nm and for samples of about 15 cm³ ablated with a setting of 5 W of 980 nm + 5 W of 1470 nm, where the volume of the ablated fibroids were 46.6% and 41.6%, respectively. **Conclusion:** This is the first *ex vivo* study with a new DWLS, which made it possible to understand which one of its settings could be recommended for the safest and best macroscopic results in myolysis.

Keywords

Uterine fibroids; Myolysis; Diode laser; DWLS; Hysteroscopy; *Ex vivo*

1. Introduction

Uterine fibroids (myomas, leiomyomas or leiomyomas) are the most common benign gynaecological tumours in women, predominantly affecting women of late fertile age. Approximately 60–70% of women experience this disease at least once in their lifetime [1]. Common risk factors are reproductive age (premenopausal) and ethnicity, as black women, are more likely to develop fibroids in their lives [2].

Most women with fibroids are asymptomatic. Symptoms arise in relation to the size and number or location of the fibroids, and frequent symptoms include abnormal uterine bleeding with anaemia, dysmenorrhea, pelvic pain and/or discomfort (linked to the bulky myoma effect), such as urinary symptoms, fatigue, and constipation, which significantly deteriorates the quality of life for the patients [2, 3]. However, heavy menstrual bleeding (HMB) is the principal manifestation of uterine fibroids and it is typically related to a submucosal location or an impaired endometrial function [3, 4]. Like the uterine septum, uterine fibroids can also impair reproductive function by generating implantation defects (submucosal or large intramural fibroids) and/or altering the uterine cavity lining [5–7]. Many attempts have been made to avoid a negative impact on pregnancy outcomes and to restore fertility after a myomectomy [8, 9].

Symptoms, age, desire to maintain fertility and patient choice are the key factors in personalizing a patient's treatment when suffering from uterine fibroids [10].

Hysteroscopic removal is the most effective treatment and is the standard minimally invasive surgical procedure for treating submucous fibroids [11–13]. Hysteroscopic myomectomy for G2 myomas is a complex procedure that should only be performed by surgeons experienced in hysteroscopy. This procedure is associated with a significant risk of complications proportional to the myoma's degree of intramural development [14, 15].

During the past three decades, various methods were developed in a mini-invasive perspective to coagulate the fibroids instead of surgically removing them. This approach is known as "myolysis" and was first performed in 1987 by Mergui in France. He used a Nd:Yag Laser to perforate the fibroid pseudo capsule, burn/coagulate the tissue, destroy its blood supply, and provoke its shrinkage in laparoscopy [16]. In the early 1990s, myoma coagulation was performed using heat

either by laser technology or a bipolar radiofrequency probe (120 Watts) in a process called thermomyolysis [17, 18]. Due to the difficulty of predicting the extent of local heat distribution, this technique had a limited diffusion, and later studies reported cases of uterine rupture during pregnancy after myoma thermomyolysis [19].

In 2004, magnetic resonance-guided Focused Ultrasound Surgery (MRgFUS) was approved to treat uterine fibroids, liver, breast, pancreatic cancers and bone metastasis [20]. MRgFUS is performed under magnetic resonance imaging (MRI) guidance with a contrast medium and a transabdominal probe that focuses on 1.5 MHz frequency ultrasound (US) emissions on the target area (of about 0.5 cm³) with a 12 cm-depth penetration from the skin surface. The US beam causes thermic necrosis of the fibroid while sparing the surrounding normal tissues [21].

Other promising techniques include microwave and radiofrequency myolysis. Microwaves, originally developed for liver tumour ablation, are a novel technology used to treat submucosal myomas. Recently, Tsuda *et al.* [22] performed this type of myolysis in women with menorrhagia caused by submucosal myomas. The shrinkage reached about 70% of the myoma's initial volume, in a safe and effective procedure.

Radiofrequency myolysis is another uterine-conserving technique. Radiofrequencies produce heat by high-frequency oscillations alternating within an electric field, causing coagulation and necrosis of the target area and inactivation of hormonal receptors on the myoma, which prevents regrowth of the fibroid tissue [23].

Recently, great interest has been focused on laser energy technology associated with mini-invasive approaches. Among laser energy technologies, currently, diode lasers demonstrated many advantages in laparoscopic [24–26] and hysteroscopic surgery (endometrial polyps, myomas and metroplasty) [27–33]. Lately, a new type of laser is available, which generates two wavelengths (980 + 1470 nm) from a diode semiconductor Dual Wavelength Diode Laser System (DWLS). The two wavelengths provide contemporary absorption in water (1470 nm) and haemoglobin (980 nm), with high performances in cutting, vaporizing and haemostasis [33].

Haimovich demonstrated how myolysis by laser-induced interstitial thermotherapy (LITT) with the Leonardo[®] diode laser DWLS (Biolitec[®], Jena, Germany) using a laser fibre working through the working canal of the Bettocchi hysteroscope (Storz[®], Tuttlingen, Germany) could be effective [32].

As the types of fibre and the safest device (Leonardo[®], Biolitec[®], Jena, Germany, DUAL 45) settings for performing effective but un-complicate myolysis are not known, we performed *ex vivo* tests on uterine fibroids obtained from women undergoing hysterectomy. The Leonardo[®] DUAL 45 is a device that allows mixing the two wavelengths: 1470 nm (mainly used for cutting) with a power from 0 to 15 Watt (W) and 980 nm (mainly used for coagulation) with a power from 0 to 30 W up to a resulting maximum of 45 W obtained

by mixing the two wavelengths. The time of using this type of laser with a specific power causes certain the energy to be measured in Joules (J) by the device.

To evaluate the diode laser DWLS ablation techniques for treating fibroids and aid in future treatment planning, we devised an experimental system for characterizing the myolysis fibre ablation performance with a particular fibre (Myolysis[®], Biolitec[®], Jena, Germany) (Fig. 1A,B), which has the characteristic of spreading the energy radially and not only in the tip that is explicitly designed to create a thermal ablation in the centre of the myoma.

The main goals of the study were:

- (1) To ensure the treatment's safety by keeping the high temperature in the external surface of the fibroids tissue.
- (2) To estimate the efficacy of the treatment in terms of the percentage of volume ablation inside the myoma.

2. Materials and methods

2.1 Patient selection

Women who underwent total laparotomic abdominal hysterectomy due to multiple uterine fibroids with diameters ranging from 1 to 8 cm of the maximum diameter at the Division of Obstetrics and Gynecology, Department of Surgical Sciences, University of Cagliari, were enrolled in this study and permitted post-operative testing of their uterine specimens. All the myomas were used for the experiment after a total hysterectomy and their excision from the fresh uteri. A total of three patients participated in the study, and measurements were obtained from 12 unique fibroids.

Written content was obtained for the informed consent of the participants. The institutional review board of the Azienda Ospedaliero Universitaria (AOU) of Cagliari approved the study, code Prot. PG/2020/10910 and the study was registered on [ClinicalTrials.gov](https://clinicaltrials.gov) PRS code NCT04748978 as a preliminary part of the *in vivo* study.

2.2 Tissue preparation, system setup and ablation procedure

Immediately following surgical removal of the uterus, each specimen was transferred from the operating room to the laboratory centre (<5 minute transit) for *ex vivo* testing. All myomas were enucleated with a scalpel while attempting to leave the pseudocapsule and areas of the myometrium to better detect the temperature on their surface. After that, all myomas were measured in all axes trying to choose myomas with the same volume to evaluate the effects of the different settings of the diode laser device.

The overall system consisted of:

- (1) a diode laser energy deposition system (Leonardo[®], Biolitec[®] DUAL 45),
- (2) a diode laser fibre (Myolysis[®], Biolitec[®]),
- (3) temperature monitoring myoma surface and water bath with a digital thermocouple thermometer,
- (4) tenaculum forceps as a holder template,
- (5) two beaker containers filled with isotonic saline water maintained at 37 °C.




Fig. 1. Macroscopic and histopathological examination of the myoma after *ex vivo* myolysis. (A) Myolysis diode laser fibre. (B) Myolysis diode laser fibre activated with the characteristic of spreading the energy radially and not only in the tip. (C) The experiment setup with the fibre mode off. (D) The experiment setup with the fibre mode on. (E) Myoma lowered into the saline water bath of the beaker container to evaluate its volume before starting the experiment. (F) Myoma lowered into the saline water bath of the beaker container to evaluate its volume after the ablation procedure.

For mimicking the physiologic conditions, the diode laser fibre and the samples were placed inside a water bath containing 0.9% isotonic saline water. The bath was maintained at human body temperature (37 °C) by manually adding warmer or colder water until the set temperature was reached. The experiment setup is illustrated in Fig. 1C,D.

The sensor position of the thermocouple thermometer from the fibroid surface and saline bath were logged before starting the experiment. Before starting the ablation procedure, each myoma was lowered into the saline water bath of the first beaker container to evaluate its volume (V), measuring the ΔV with the pre-existing mL of water (Fig. 1E).

The myolysis was performed as follows: a diode laser fibre was inserted parallel (with 90° insertion angle) inside the myoma reaching the core and was then lowered into the saline water bath of the second beaker container (used only for the myolysis phase). For example, in a 3 × 3 cm fibroid, the fibre was inserted for 1.5 cm in order to reach the centre of the myoma and be able to emit energy radially at different power settings, measured in W, and reaching different energy levels, measured in J, as shown in Table 1.

In contrast to other applications of thermal ablation, such as tumour ablation, the maximum efficiency of ablation in fibroids would be limited by an additional safety constraint,

Table 1. Myolysis *ex vivo* effects on fibroid samples.

Experimental set	Diameters of the fibroid (cm)	Fibroid Volume (cm ³) pre-treatment	Fibroid Volume (cm ³) post-treatment	Volume of the fibroid ablation (%)	Energy (J) reached when the experiment was stopped
Sample 1	4.1 × 3.8 × 3.5	114	86	24.56%	8500
Set 1 Sample 2	3.2 × 2.8 × 3.0	56	45	16.07%	5500
Sample 3	2.2 × 1.9 × 1.8	16	15	6.25%	800
Sample 1	4.3 × 3.6 × 3.9	126	95	24.6%	9000
Set 2 Sample 2	3.2 × 2.9 × 3.1	60	49	18.33%	5000
Sample 3	2.1 × 2.0 × 1.9	17	16	5.88%	900
Sample 1	4.4 × 3.5 × 3.8	122	85	30.32%	10000
Set 3 Sample 2	3.1 × 3.0 × 3.1	60	32	46.6%	5000
Sample 3	2.0 × 1.8 × 1.7	13	10	23.07%	1500
Sample 1	3.8 × 3.5 × 4.0	111	82	26.12%	12000
Set 4 Sample 2	2.8 × 3.2 × 2.7	51	33	35.29%	5000
Sample 3	1.8 × 2.0 × 1.6	12	7	41.6%	1000

i.e., precluding collateral thermal damage in adjacent tissues. The clinical objective in thermal ablation techniques is to expose the fibroid tissue to ablative temperatures (>55 °C), (direct necrosis occurs at temperatures above 60 °C, as most tissue proteins denature within a few seconds) while protecting the adjacent myometrium (thermal dose ≤10 CEM 43, which equates to approximately 47 °C) [34, 35]. Hence, the energy deposition was stopped whenever any sensor on myoma surface accumulated more than the safety threshold of ~47 °C, another hole appeared on opposite (or another) side to the entrance area of the laser fibre or 10 minutes had passed since the start of the procedure.

After the ablation procedure, each myoma was again inserted in the first beaker container to evaluate the ΔV with the previous V measured before starting the experiment (Fig. 1F).

Following the thermal property measurements, the specimens were delivered to the pathology lab for standard post-surgical processing and analysis. Macroscopic and Hematoxylin and Eosin (H&E) stained sections were reviewed by the pathologists (DF and GF) after the original histopathologic diagnoses were verified.

3. Results

Table 1 shows the fibroid volume and energy achieved for each sample when the experiment was stopped.

Set 1 was set out with the maximum power of the device (30 W of 980 nm + 15 W of 1470 nm). Set 2 was set out with 15 W of 980 nm + 15 W 1470 nm. Set 3 was set out with 10 W of 980 nm + 10 W of 1470 nm. Set 4 was set out with 5 W of 980 nm + 5 W of 1470 nm. Each of the four sets was used on three fibroids samples ranging from 12 to 126 cm³.

Based on the results shown in Table 1, the ablation coverage of fibroids was less than 100%. The maximum ablation coverage achieved with the set 3 on a myoma of 60 cm³ was 46.6%. This result was expected, since the ablations were stopped when the temperature on the myoma surface started to reach the safety threshold of ~47 °C, which limited the ab-

lation extent. For each of the four sets, the energy reached when the experiment was stopped is shown.

For sets 1 and 2, the powers are too high for these volumes of myomas, as the experiment was stopped after a few minutes due to the reaching of the threshold temperature on the surface or even due to the presence of a hole in the opposite part of the entrance of the laser fibre. When the device was set up with such high powers (sets 1 and 2) and used on myomas with a volume not exceeding 120 cm³, the laser fibre tended to go straight, bisecting the fibroid in two halves; in fact, the volume of the ablated fibroids did not exceed 25%. Contrariwise, good results were found for set 3 with fibroids of about 3 cm (~60 cm³) and for set 4 with samples of about 2 cm (~15 cm³) where the volume of the ablated fibroids were 46.6% reaching 5000 J of energy, and 41.6% reaching 1000 J of energy, respectively.

Fig. 2 shows the macroscopic (Fig. 2A) and histopathological examination (Fig. 2B,C). In particular, Fig. 2A shows the macroscopic effect of the set 3 sample 2 ablation with the vaporization of the core of the myoma. The shrinkage of the myoma was not reported; however, we observed that the core of the fibroid was vaporized by reducing its volume by almost 50% and keeping its external surfaces intact.

4. Discussion

Women are constantly in need of minimally invasive solutions for the therapy of symptomatic fibroids. Laparoscopic or laparotomic hysterectomy, laparoscopic or laparotomic myomectomy, and hysteroscopic myomectomy are the standard procedures, many of which may trigger physical and mental distress [10]. The standard method of hysteroscopic myomectomy includes the use of a 10-mm surgical hysteroscope, which necessarily involves cervical dilatation, anaesthesia, and hospitalization. The treatment requires the myoma slicing with the cutting loop on the fibroid surface [14].

Myomas greater than 3 cm and/or positioned in the fundus or lateral walls have a higher risk of surgical failure than smaller fibroids as well as those placed in the anterior or




Fig. 2. Macroscopic and histopathological examination of the myoma after *ex vivo* myolysis. (A) The leiomyoma was freshly cut by creating slices proceeding from the fibre entry point to the opposite diametral point. (B) Histological picture of the burn feature in smooth muscle cells from a uterine leiomyoma. The cell nuclei disappeared, the cell shapes changed from fascicles to irregular tapes due to many vacuum artifacts, and the vessels look obliterated. The bar measures a length of 0.855 mm from where the tissue shows again its usual morphology (hematoxylin eosin stain). (C) Low power field of a leiomyoma showing the characteristic scorching artifacts from the surgical procedure. Huge and many irregular vacuums can be seen for the length of 0.565 mm measured by the black bar (hematoxylin eosin stain).

posterior walls. Hysteroscopic surgical procedures can remove the myoma completely only in cases where the fibroid is mainly within the uterine cavity (G0 and G1) and focuses on removing tiny fibroid tissue fragments [36]. Therefore, in recent years, less invasive approaches have caught the interest of researchers. Several conservative procedures have been utilized to discourage hysterectomy or myomectomy, such as radiofrequency and MRgFUS or microwaves myolysis [20–23].

The safety and feasibility of radiofrequency treatments in uterine fibroids have been reported in numerous studies [23, 37, 38]. This technique requires a probe insertion into the myoma by using ultrasonic real-time imaging to direct

the procedure. Radiofrequency treatments were shown to reduce the volume of myomas by more than half [37]. Patients tolerate this form of myolysis well, and it has a variety of benefits, including no post-ischemic pain and a fast recovery [37]. However, there are some disadvantages in using radiofrequency effects, such as the complexity in providing a histopathological diagnosis of the tissue, performing transvaginal sonography, and the need for follow-up analyses, such as the inspection of the intrauterine tissue after treatment [38].

MRgFUS have the advantage of being able to identify the precise position of uterine myomas. The literature shows that fibroids react to MRgFUS treatment in a variety of ways.

The amount of sonication power required for ablation varies significantly between patients and even within fibroids. Fibroids with a brighter T2-weighted signal strength (T2wSI) are more complicated to ablate, resulting in lower nonperfused volume ratios immediately after treatment and worse long-term outcomes. Increased vascularization, fluid-rich tissues, high cellularity, and/or degeneration have all been related to high T2wSI in fibroids [39, 40].

Microwaves, which were originally designed for liver tumour ablation, are a novel treatment for submucosal myomas. One of the disadvantages of using microwaves occurs when the myoma is localized in the sidewalls, and the applicator's angle of use is not 90°. When the applicator is inserted at 67.5°, the ablation coverage is substantially reduced. The average ablation efficiency decreases from 66% in the 90° case to 17% in the 67.5° case. The device's heating pattern is concentrated around the applicator's shaft. The clinical consequence is that the applicator's approach angle in the fibroid determines the form and scale of ablations [34].

To overcome the limitations of the techniques described above, we thought it could be advantageous to use a DWLS diode laser working through the working canal of the Bettocchi hysteroscope (Storz®) to perform the myolysis allowing for the direct visualization and localization of the fibroid as well as the possibility of having a histological examination and performing the procedure in an office setting without anaesthesia. In fact, as we showed in previous studies, pain is minimized thanks to the progress in technical instruments (size and type of device, distension media) and with increased gynaecologist experience [41–44], in addition to preoperative hormonal therapies (gonadotropin-releasing hormone analogues or progestins), which provide better conditions during the operating session, due to the thinning of the endometrial thickness and volumetric reduction of the myoma [45].

The diode laser previously demonstrated good results in hysteroscopic polypectomy and metroplasty demonstrating extreme precision of cutting, precise and constant control of tissue vaporization in the complete absence of bleeding, controlled power of penetration/deepening, a high capacity of hemostasis, the absence of electrical interferences, high safety and good compliance by the patients [27, 28]. Due to the physical characteristics of the two wavelengths, using the diode laser to perform myolysis could be revolutionary: the 1470 nm vaporizes tissues in the close surroundings, while the 980 nm, which achieves high absorption for haemoglobin, coagulates blood vessels over a larger area providing a high capacity for ablation [32]. Theoretically, from a scientific point of view, the wavelength of 1470 nm used for a long time inside the myoma could be enough to cause the tissue's vaporization. Following the already known *in vivo* experiment of Hamovich, our aim will be to achieve HMB improvement of the treated patients and not to make the myoma disappear [32]. Therefore, the 980 nm, thanks to its affinity for haemoglobin, could be fundamental to reduce the vascularization of the myoma even if it can lead to a rapid increase in heat on the treated surface. Hence, even if the myoma has been not fully vaporized, the vascularity could be impaired.

larization of the myoma even if it can lead to a rapid increase in heat on the treated surface. Hence, even if the myoma has been not fully vaporized, the vascularity could be impaired.

This experimental study represents only an *ex vivo* and preliminary test for the *in vivo* study we plan to carry out in which the most important outcome will be the resolution of the symptoms (in particular HMB) for our patients who have no desire for pregnancy. In fact, while some authors support pregnancy after myolysis, other studies mentioning uterine rupture cases during pregnancy highly recommend that myolysis is only approved for women who do not desire future pregnancy [18, 19]. Another factor to be considered for the *in vivo* study, will be the possible damage that this technique may have on the endometrium's basal layer, where the stem cells are most represented. Adult stem cells have been found in both human and mouse endometrium, indicating that epithelial progenitor cells and mesenchymal stem/stromal cells play essential roles in the cyclical regeneration of endometrial epithelium and stroma. Heat-induced inflammation may also inhibit the regeneration of traumatized endometrium by injuring stem/progenitor cells or causing their loss through the production of inflammatory mediators and fibrotic tissue formation [46].

Good macroscopic results have been found for fibroids of about 3 cm (~60 cm³) and for samples of about 2 cm (~15 cm³). For fibroids with a volume greater than 100 cm³ we think that the best strategy is to use set 3 for a longer time (more than 10 minutes) rather than increasing the power as in set 1 and 2, thus avoiding that the laser energy could go straight.

There were certain limitations to this study: (1) the anatomical heterogeneity among and within uterine fibroids, as revealed by differences in total collagen, collagen types, water component, gross appearance, and mechanical variations, makes it very difficult for determinate the exact amount of time/energy that will work for all the fibroids [47]; (2) blood perfusion effects were not considered; (3) half of the fibroid is typically inside the myometrium, and the other half is in the uterine cavity, but in our study, it was not possible to take into account the attenuation of the temperature on the myoma surface by the myometrium; and (4) all of our tests were performed by inserting the fibre at a 90° and reaching the fibroid's centre. This procedure may be difficult to perform *in vivo* in a lateral wall myoma, for example.

5. Conclusions

To our knowledge, this is the first *ex vivo* study with a new DWLS, which made it possible to understand which one of the settings of the Leonardo®, Biolitec® DUAL 45 could be recommended for the safest and best macroscopic results in myolysis. The possibility of having a direct hysteroscopic visualization of the myoma, of being able to use this technique without narcosis and of having the possibility to stop when the patient feels hot leads us to think that this could be an alternative and safe technique in the execution of hysteroscopic

myolysis. Further studies *in vivo* are necessary, however, to explore the feasibility and reproducibility of the technique.

Abbreviations

CEM, Cumulative Equivalent Minutes; DWLS, Dual Wavelengths System; H&E, Hematoxylin and Eosin; HMB, Heavy Menstrual Bleeding; kHz, kilo Hertz; LITT, Laser-induced Interstitial Thermotherapy; MHz, Mega Hertz; MRgFUS, Magnetic Resonance-guided Focused Ultrasound; MRI, Magnetic Resonance Imaging; Nd:YAG, Neodymium-doped Yttrium Aluminum Garnet; T2wSI, T2-weighted Signal strength; US, Ultrasound.

Author contributions

MND, FrSc, SA, FeSo and LN conceived and designed the experiment; MND and FrSc performed the experiment; DF, GF, and SA participated in coordination of the study; DF and GF analyzed the samples; MND, ASL and MN wrote the paper; Feso, LN, ASL and MN helped in drafting the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written content was obtained with the informed consent of the participant. The institutional review board of the Azienda Ospedaliero Universitaria of Cagliari approved the study, code Prot. PG/2020/10910 and the study was registered on [ClinicalTrials.gov](https://clinicaltrials.gov) PRS code NCT04748978 as a preliminary part of the *in vivo* study.

Acknowledgment

This publication was created as part of a research project financed with the resources of P.O.R. SARDEGNA F.S.E. 2014-2020 - Asse III "Istruzione e Formazione, Obiettivo Tematico: 10, Obiettivo Specifico: 10.5, Azione dell'accordo fi Partenariato: 10.5.12" Avviso di chiamata per il finanziamento di Progetti di ricerca - Anno 2017.

Funding

This research received no external funding.

Conflict of interest

The authors declare no conflict of interest.

References

- [1] Bulun SE. Uterine fibroids. *New England Journal of Medicine*. 2013; 369: 1344–1355.
- [2] Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. *American Journal of Obstetrics and Gynecology*. 2003; 188: 100–107.
- [3] Zimmermann A, Bernuit D, Gerlinger C, Schaeffers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. *BMC Women's Health*. 2012; 12: 6.
- [4] Munro MG, Critchley HO, Broder MS, Fraser IS. Figo working group on menstrual disorders: FIGO classification system for causes of abnormal uterine bleeding in nonpregnant women of reproductive age. *International Journal of Gynecology & Obstetrics*. 2011; 113: 1–13.
- [5] Loddo A, D'Alterio MN, Neri M, Masala F, Cane FL, Melis GB. Pregnancy Complications after Hysteroscopic Metroplasty: a Ten-Year Case-Control Study. *Surgical Technology International*. 2017; 30: 205–209.
- [6] Daniilidis A, Kalpatsanidis A, Kalkan U, Kamas S, Pados G, Angioni S. Reproductive outcome after operative hysteroscopy for uterine septum: scissors or diathermy? *Minerva Ginecologica*. 2020; 72: 36–42.
- [7] Zepiridis LI, Grimbizis GF, Tarlatzis BC. Infertility and uterine fibroids. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2016; 34: 66–73.
- [8] Metwally M, Raybould G, Cheong YC, Horne AW. Surgical treatment of fibroids for subfertility. *Cochrane Database of Systematic Reviews*. 2020; 1: CD003857.
- [9] Litta P, Conte L, De Marchi F, Saccardi C, Angioni S. Pregnancy outcome after hysteroscopic myomectomy. *Gynecological Endocrinology*. 2014; 30: 149–152.
- [10] Angioni S, D'Alterio MN, Daniilidis A. Highlights on Medical Treatment of Uterine Fibroids. *Current Pharmaceutical Design*. 2021. (in press)
- [11] Saccardi C, Conte L, Fabris A, De Marchi F, Borghero A, Gizzo S, et al. Hysteroscopic enucleation in toto of submucous type 2 myomas: long-term follow-up in women affected by menorrhagia. *Journal of Minimally Invasive Gynecology*. 2014; 21: 426–430.
- [12] Salazar CA, Isaacson KB. Office Operative Hysteroscopy: an Update. *Journal of Minimally Invasive Gynecology*. 2018; 25: 199–208.
- [13] Alkatout I, Mettler L, Günther V, Maass N, Eckmann-Scholz C, Eleassawy M, et al. Safety and economical innovations regarding surgical treatment of fibroids. *Minimally Invasive Therapy & Allied Technologies*. 2016; 25: 301–313.
- [14] Di Spiezo Sardo A, Mazzon I, Bramante S, Bettocchi S, Bifulco G, Guida M, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. *Human Reproduction Update*. 2008; 14: 101–119.
- [15] Cooper JM, Brady RM. Intraoperative and early postoperative complications of operative hysteroscopy. *Obstetrics and Gynecology Clinics of North America*. 2000; 27: 347–366.
- [16] Herbert AG. Myolysis revisited. *JLSLS*. 2008; 12: 426–430.
- [17] Goldfarb HA. Comparison of Bipolar Electrocoagulation and Nd:YAG Laser Coagulation for Symptomatic Reduction of Uterine Myomas. *Journal of the American Association of Gynecologic Laparoscopists*. 1994; 1: S13.
- [18] Donnez J, Squifflet J, Polet R, Nisolle M. Laparoscopic myolysis. *Human Reproduction Update*. 2000; 6: 609–613.
- [19] Arcangeli S, Pasquarrette MM. Gravid uterine rupture after myolysis. *Obstetrics and Gynecology*. 1997; 89: 857.
- [20] Zhou YF. High intensity focused ultrasound in clinical tumor ablation. *World Journal of Clinical Oncology*. 2011; 2: 8–27.
- [21] Stewart EA, Gedroyc WMW, Tempany CMC, Quade BJ, Inbar Y, Ehrenstein T, et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. *American Journal of Obstetrics and Gynecology*. 2003; 189: 48–54.
- [22] Tsuda A, Kanaoka Y. Outpatient transcervical microwave myolysis assisted by transabdominal ultrasonic guidance for menorrhagia caused by submucosal myomas. *International Journal of Hyperthermia*. 2015; 31: 588–592.
- [23] Yin G, Chen M, Yang S, Li J, Zhu T, Zhao X. Treatment of uterine myomas by radiofrequency thermal ablation: a 10-year retrospective cohort study. *Reproductive Sciences*. 2015; 22: 60–614.
- [24] Angioni S, Pontis A, Sorrentino F, Nappi L. Bilateral salpingo-oophorectomy and adhesiolysis with single port access laparoscopy and use of diode laser in a BRCA carrier. *European Journal of Gynaecological Oncology*. 2015; 36: 479–481.

- [25] Angioni S, Mais V, Pontis A, Peiretti M, Nappi L. First case of prophylactic salpingectomy with single port access laparoscopy and a new diode laser in a woman with BRCA mutation. *Gynecological Oncology Case Reports*. 2014; 9: 21–23.
- [26] Nappi L, Angioni S, Sorrentino F, Cinnella G, Lombardi M, Greco P. Anti-Mullerian hormone trend evaluation after laparoscopic surgery of monolateral endometrioma using a new dual wavelengths laser system (DWLS) for hemostasis. *Gynecological Endocrinology*. 2016; 32: 34–37.
- [27] Nappi L, Sorrentino F, Angioni S, Pontis A, Litta P, Greco P. Feasibility of hysteroscopic endometrial polypectomy using a new dual wavelengths laser system (DWLS): preliminary results of a pilot study. *Archives of Gynecology and Obstetrics*. 2017; 295: 3–7.
- [28] Nappi L, Pontis A, Sorrentino F, Greco P, Angioni S. Hysteroscopic metroplasty for the septate uterus with diode laser: a pilot study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2016; 206: 32–35.
- [29] Esteban Manchado B, Lopez-Yarto M, Fernandez-Parra J, Rodriguez-Oliver A, Gonzalez-Paredes A, Laganà AS, *et al*. Office hysteroscopic metroplasty with diode laser for septate uterus: a multicenter cohort study. *Minimally Invasive Therapy & Allied Technologies*. 2020; 22: 1–7.
- [30] Haimovich S, Mancebo G, Alameda F, Agramunt S, Solé-Sedeno JM, Hernández JL, *et al*. Feasibility of a new two-step procedure for office hysteroscopic resection of submucous myomas: results of a pilot study. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*. 2013; 168: 191–194.
- [31] Haimovich S, López-Yarto M, Urresta Ávila J, Saavedra Tascón A, Hernández JL, Carreras Collado RC. Office Hysteroscopic Laser Enucleation of Submucous Myomas without Mass Extraction: a Case Series Study. *BioMed Research International*. 2015; 2015: 905204.
- [32] Haimovich S. Breaking the limits on office hysteroscopy myomectomy. In Tinelli A, Alonso Pacheco L, Haimovich S (eds.) *Hysteroscopy* (pp. 555–561). Denmark: Springer, Cham. 2018.
- [33] Nappi L, Sorrentino F, Angioni S, Pontis A, Greco P. The use of laser in hysteroscopic surgery. *Minerva Ginecologica*. 2016; 68: 722–726.
- [34] Zia G, Sebek J, Alvarez E, Prakash P. Assessment of thermal damage to myometrium during microwave ablation of uterine fibroids. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. 2020; 2020: 5263–5266.
- [35] Dahl O, Overgaard J. Hyperthermia. In Souhami R, Tannock I, Hoenborg P, Horiot J (eds.) *Oxford Textbook of Oncology* (pp. 511–525). 2nd edn. Oxford: Oxford University Press. 2001.
- [36] Bettocchi S, Di Spiezio Sardo A, Ceci O, Nappi L, Guida M, Greco E, *et al*. A new hysteroscopic technique for the preparation of partially intramural myomas in office setting (OPPIuM technique): a pilot study. *Journal of Minimally Invasive Gynecology*. 2009; 16: 748–754.
- [37] Turtulici G, Orlandi D, Dedone G, Mauri G, Fasciani A, Sirito R, *et al*. Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study. *International Journal of Hyperthermia*. 2019; 35: 97–104.
- [38] Liu SJ, Lv W, Shi M, Bi BL, Wang HD. Hysteroscopic outcomes after radiofrequency ablation of myomas: Two case reports and literature review. *Clinical Experimental Obstetrics and Gynecology*. 2020; 47: 991–993.
- [39] Zhao WP, Zhang J, Han ZY, Yao JP, Zhou X, Liang P. A clinical investigation treating different types of fibroids identified by MRI-T2WI imaging with ultrasound guided high intensity focused ultrasound. *Scientific Reports*. 2017; 7: 10812.
- [40] Dillon C, Rezvani M, McLean H, Adelman M, Dassel M, Jarboe E, *et al*. A tissue preparation to characterize uterine fibroid tissue properties for thermal therapies. *Medical Physics*. 2019; 46: 3344–3355.
- [41] Pluchino N, Ninni F, Angioni S, Artini P, Araujo VG, Massimetti G, *et al*. Office vaginoscopic hysteroscopy in infertile women: effects of gynecologist experience, instrument size, and distention medium on patient discomfort. *Journal of Minimally Invasive Gynecology*. 2010; 17: 344–350.
- [42] Litta P, Leggieri C, Conte L, Dalla Toffola A, Multinu F, Angioni S. Monopolar versus bipolar device: safety, feasibility, limits and perioperative complications in performing hysteroscopic myomectomy. *Clinical and Experimental Obstetrics & Gynecology*. 2014; 41: 335–338.
- [43] Litta P, Fantinato S, Calonaci F, Cosmi E, Filippeschi M, Zerbetto I, *et al*. A randomized controlled study comparing harmonic versus electrosurgery in laparoscopic myomectomy. *Fertility and Sterility*. 2010; 94: 1882–1886.
- [44] Abis P, Bigozzi MA, Dotto J, Petriglia C, Neri M, Cornacchia S, *et al*. Pain management during office hysteroscopy: a survey of hysteroscopists. *Surgical Technology International*. 2020; 37: 161–166.
- [45] Florio P, Imperatore A, Litta P, Franchini M, Calzolari S, Angioni S, *et al*. The use of nomegestrol acetate in rapid preparation of endometrium before operative hysteroscopy in pre-menopausal women. *Steroids*. 2010; 75: 912–917.
- [46] Gargett CE, Nguyen HPT, Ye L. Endometrial regeneration and endometrial stem/progenitor cells. *Reviews in Endocrine & Metabolic Disorders*. 2012; 13: 235–251.
- [47] Jayes FL, Liu B, Feng L, Aviles-Espinoza N, Leikin S, Leppert PC. Evidence of biomechanical and collagen heterogeneity in uterine fibroids. *PLoS ONE*. 2019; 14: e0215646.